0000899243-20-012309.txt : 20200507 0000899243-20-012309.hdr.sgml : 20200507 20200507193935 ACCESSION NUMBER: 0000899243-20-012309 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20200507 FILED AS OF DATE: 20200507 DATE AS OF CHANGE: 20200507 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: aMoon 2 Fund Limited Partnership CENTRAL INDEX KEY: 0001744099 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39279 FILM NUMBER: 20858249 BUSINESS ADDRESS: STREET 1: 34 YERUSHALAYIM RD. CITY: RAANANA STATE: L3 ZIP: 4350110 BUSINESS PHONE: 972(73)3989560 MAIL ADDRESS: STREET 1: 34 YERUSHALAYIM RD. CITY: RAANANA STATE: L3 ZIP: 4350110 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Ayala Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001797336 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 823578375 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1313 N. MARKET STREET STREET 2: SUITE 5100 CITY: WILMINGTON STATE: DE ZIP: 19801 BUSINESS PHONE: (857) 444-0553 MAIL ADDRESS: STREET 1: 1313 N. MARKET STREET STREET 2: SUITE 5100 CITY: WILMINGTON STATE: DE ZIP: 19801 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2020-05-07 0 0001797336 Ayala Pharmaceuticals, Inc. AYLA 0001744099 aMoon 2 Fund Limited Partnership 34 YERUSHALAIM RD. BEIT GAMLA, 6TH FLOOR RA'ANANA 4350110 0 0 1 0 Common Stock 1313318 D Series A Preferred Stock Common Stock 369231 D Series B Preferred Stock Common Stock 508924 D The preferred stock is convertible at any time, at the holder's election and has no expiration date. Each share of preferred stock shall be automatically converted into one (1) share of common stock upon the closing of the Issuer's initial public offering. Exhibit 24 - Power of Attorney. /s/ Shachar Hadar, Adv., Haim Gueta, Adv., Matthew Rudolph, Adv., and Daniel Colthof, Adv., Attorney-in-Fact for Yair Schindel 2020-05-07 EX-24 2 attachment1.htm EX-24 DOCUMENT

                                                                      Exhibit 24

                               POWER OF ATTORNEY

       With respect to holdings of and transactions in securities issued by
Ayala Pharmaceuticals, Inc. (the "Company"), the undersigned hereby constitutes
and appoints the individuals named on Schedule A attached hereto and as may be
amended from time to time, or any of them signing singly, with full power of
substitution and resubstitution, to act as the undersigned's true and lawful
attorney-in-fact to:

    1.  prepare, execute in the undersigned's name and on the undersigned's
        behalf, and submit to the United States Securities and Exchange
        Commission (the "SEC") a Form ID, including amendments thereto, and any
        other documents necessary or appropriate to obtain and/or regenerate
        codes and passwords enabling the undersigned to make electronic filings
        with the SEC of reports required by Section 16(a) of the Securities
        Exchange Act of 1934, as amended, or any rule or regulation of the SEC;

    2.  execute for and on behalf of the undersigned, Forms 3, 4, and 5 in
        accordance with Section 16 of the Securities Exchange Act of 1934, as
        amended, and the rules thereunder;

    3.  do and perform any and all acts for and on behalf of the undersigned
        which may be necessary or desirable to complete and execute any such
        Form 3, 4, or 5, complete and execute any amendment or amendments
        thereto, and timely file such form with the SEC and any stock exchange
        or similar authority; and

    4.  take any other action of any type whatsoever in connection with the
        foregoing which, in the opinion of such attorney-in- fact, may be of
        benefit to, in the best interest of, or legally required by, the
        undersigned, it being understood that the documents executed by such
        attorney-in-fact on behalf of the undersigned pursuant to this Power of
        Attorney shall be in such form and shall contain such terms and
        conditions as such attorney-in-fact may approve in such attorney-in-
        fact's discretion.

    The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution and
resubstitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorneys-in-fact substitute or substitutes, shall
lawfully do or cause to be done by virtue of this Power of Attorney and the
rights and powers herein granted.

       The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Securities Exchange Act of 1934, as amended. This Power
of Attorney shall remain in full force and effect until the undersigned is no
longer required to file Forms 3, 4, and 5 with respect to the undersigned's
holdings of and transactions in securities issued by the Company, unless earlier
revoked by the undersigned in a signed writing delivered to the foregoing
attorneys-in-fact.

       IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this seventh day of May, 2020.

                                        Signature: /s/ Yair Schindel
                                        ------------------------
                                        Print Name: Yair Schindel
                                        Title:      Managing Partner, aMoon
                                                    2 Fund Limited
                                                    Partnership


                                   Schedule A

       Individuals Appointed as Attorney-in-Fact with Full Power of Substitution
and Resubstitution

Shachar Hadar, Adv.
Haim Gueta, Adv.
Matthew Rudolph, Adv.
Daniel Colthof, Adv.